Latisse contains bimatoprost 0.03% w/v (0.3mg/mL), a synthetic prostaglandin analogue indicated for the treatment of eyelash hypotrichosis, a condition characterized by inadequate or insufficient eyelashes. Treatment increases eyelash growth, including length, thickness, and darkness. Latisse remains a marketed prescription medication in Canada.
Bimatoprost is a prostaglandin analogue that influences the natural eyelash growth cycle. Although the exact mechanism responsible for eyelash growth has not been completely established, its activity is associated with increasing the proportion of eyelash follicles in the anagen, or active growth, phase and extending the period during which lashes continue to grow. The resulting changes can include increased eyelash length, thickness, pigmentation, and number.
Latisse is applied to the skin of the upper eyelid margin at the base of the eyelashes, rather than routinely instilled directly into the eye for its eyelash growth indication. Canadian product information classifies Latisse as a topical solution containing bimatoprost 0.03%.
This product provides:
- Active Ingredient: Bimatoprost
- Strength: 0.03% w/v (0.3mg/mL)
- Volume: 3mL
- Drug Class: Prostaglandin Analogue
- Primary Indication: Eyelash Hypotrichosis
- Dosage Form: Topical Solution
Consistent treatment is required to maintain the cosmetic effect. If treatment is discontinued, increased eyelash growth is expected to gradually return toward the pre treatment appearance over time. Applying additional solution beyond the recommended amount does not increase eyelash growth.
Important safety considerations include eyelid skin darkening, eye irritation, redness, itching, and unwanted hair growth in areas where the solution repeatedly contacts the skin. Bimatoprost products can also cause increased pigmentation of the iris. Iris pigmentation may be permanent, while eyelid skin pigmentation may be reversible in some patients after discontinuation.
Patients with a history of abnormal intraocular pressure, active eye inflammation, macular edema risk factors, or those using other prostaglandin analogue eye medications should discuss Latisse with an appropriate healthcare professional before use.
Latisse 0.03% is classified as a prescription medication in Canada and should be used according to the directions provided by a qualified healthcare professional.
